This is a working overview of GHS-R1a, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
==== Environmental Mitigation ==== Reducing pharmaceutical waste in water systems and soil through improved waste management. Addressing resistance genes in wastewater from hospitals, farms, and drug manufacturing sites.
=== 1910s === In 1912, the Institute of Biomedical Science was founded in the United Kingdom. The institute is still standing today and still regularly publishes works in the major breakthroughs in disease treatments and other breakthroughs in the field 117 years later. The IBMS today represents approximately 20,000 members employed mainly in National Health Service and private laboratories.
== Further reading == ABC News gallery of Cheese seized by the Dallas ISD Pantazi, Andrew. "‘Cheese’ heroin led Dallas 13-year-old to a life on the edge." The Dallas Morning News. 29 December 2012. Updated 30 December 2012. Dave Montgomery. "Law enforcement worries 'cheese heroin' could spread," McClatchy Newspapers, July 18, 2007. Maxwell, Jane C., PhD (Senior Research Scientist, University of Texas at Austin Gulf Coast Addiction Technology Transfer Center). "“Cheese” Heroin: Status as of May 2, 2007" (Archive) Merlan, Anna. "In Suburban Dallas, Loosening "Cheese" Heroin's Deadly Grip Archived 2013-10-13 at the Wayback Machine." Dallas Observer. July 28, 2011. Merlan, Anna. "Why Does Dallas Keep Forgetting About its Cheese-Heroin Problem? Archived 2012-12-24 at the Wayback Machine" Dallas Observer. May 21, 2012. "Dallas Man Sentenced to a Total of 240 Months in Federal Prison for Role in Heroin Distribution Conspiracies." (Archive[link removed]) United States Department of Justice. November 5, 2013. Tracy Sabo. "Deadly $2 heroin targets teens," CNN, June 12, 2007. "New Drug Hits the Street? A 'Poor Man's Heroin' For Kids", Pine Magazine, June 12, 2007.
Actor Bill Cosby admitted in a 2015 civil deposition to giving methaqualone to women before allegedly sexually assaulting them. Film director Roman Polanski was convicted in 1977 of sexually assaulting a 13-year-old girl after giving her alcohol and methaqualone.
=== Ultrasound === Hepatomegaly is consistently identified with an abdominal ultrasound; however, it is also commonly found in diabetic cats without hypersomatotropism. Other findings from an abdominal ultrasound include: renomegaly, pelvic dilation, an enlarged pancreas, splenomegaly and bilateral adrenomegaly. The size of the adrenal glands can be useful in diagnosis, studies have found that the size of the adrenal gland in diabetic cats without hypersomatotropism does not differ significantly from non-diabetic cats; however, adrenomegaly is not pathognomonic to hypersomatotropism and can occur with other conditions in cats such as pituitary-dependent hypercortisolism.
Sources: en.wikipedia.org
Although Arkansas, whose capitol building had recently appeared in Under Siege, came under consideration, Mississippi was chosen as the central location after Governor Ray Mabus, then involved in a lobbying campaign to woo Hollywood to his state, personally signed on to allow use of his own statehouse in February. Two months of location scouting took place in spring 1990 across East Louisiana, Western Alabama and both North Mississippi and the Gulf Coast.
Teneurin C-terminal associated peptides (TCAPs) are a family of highly conserved 40–41 amino acid peptides encoded within the C-terminus of the type II transmembrane proteins known as teneurins that are involved with cell adhesion. TCAPs are proposed to be liberated by proteolytic cleavage from the parent protein. Once released, TCAPs have been shown in have been shown in HEK293 cell assays and rodent models to act as to act as soluble neuromodulatory and metabolic regulators that influence neuronal morphology, synaptic connectivity, and stress responsiveness, in part via cytoskeletal remodeling, enhanced energy generating oxidative metabolism in some contexts, and based on in vitro studies, functional interaction with adhesion GPCRs of the latrophilin family.
== Haas atomic model == In 1910, Arthur Erich Haas proposed a model of the hydrogen atom with an electron circulating on the surface of a sphere of positive charge. The model resembled Thomson's plum pudding model, but Haas added a radical new twist: he constrained the electron's potential energy,
Hitchens stated, "[an] unborn child seems to me to be a real concept. It's not a growth or an appendix. You can't say the rights question doesn't come up. I don't think a woman should be forced to choose, or even can be", and, "as a materialist, I think it has been demonstrated that an embryo is a separate body and entity". Showing a desire to recognise the unborn as a life, he also affirmed a need for the right to abortion, stating, "the second-best fallback solution, which may sometimes be desirable for other reasons, is termination of pregnancy... all thinking people recognise a painful conflict of rights and interest in this question". Hitchens opposed an overturning of Roe v. Wade and instead hoped for science to develop new solutions to unwanted pregnancies "that will make abortion more like a contraceptive procedure than a surgical one." He strongly criticized the encouragement of sexual abstinence within the anti-abortion movement of the Christian right, and the equating of contraceptives to abortion, as expressed by Mother Teresa and representatives of the Roman Catholic Church.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.